Previous 10 | Next 10 |
Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA PR Newswire Priority Review granted by US-FDA March 28, 2022 VILLEPINTE, France , March 29, 2022 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a gl...
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, April 1, 2022, at 12:00 p.m....
The past year was a transformational time for Global Blood Therapeutics. The company was able to report growth for its flagship product, Oxbryta, in the face of COVID-19 headwinds. The company recently reported mixed earnings and revealed a hefty cash position. Global Blood Therap...
SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced it is accepting proposals for the Access to Care Empowerment for Sickle Cell (ACE) Grant Program , ...
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q4 2021 Earnings Call Feb 23, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q4 2021 Earnings Call Transcript ...
Global Blood Therapeutics, Inc. (GBT) Q4 2021 Earnings Conference Call February 23, 2022 04:30 PM ET Company Participants Ted Love - President and CEO Jeff Farrow - Chief Financial Officer David Johnson - Chief Commercial Officer Kim Smith-Whitley - EVP and Head of R&D Steven Immergut - S...
Global Blood Therapeutics press release (NASDAQ:GBT): Q4 GAAP EPS of -$1.36 misses by $0.23. Revenue of $56.1M (+35.8% Y/Y) beats by $0.65M. Cash, cash equivalents, and marketable securities totaled $734.8 million at December 31, 2021, compared with $560.9 million at&...
Achieved Oxbryta ® (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year Executed on key growth opportunities highlighted by pediatric label expansion in the U.S., marketing authoriza...
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2021 financial results on Wednesday, February 23, 2022, after U.S. financial markets close. Mana...
Global Blood Therapeutics (NASDAQ:GBT) Oxbryta was approved by the European Commission (EC) to treat hemolytic anemia due to sickle cell disease (SCD) in patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). The company said Oxbryta (vox...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...